| 今开：0.341 | 昨收：0.3462 |
| 最高：0.407 | 最低：0.333406 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：9911941.0 |
产业链观察2023-07-06 19:57
#药闻简讯# $Kazia Therapeutics(KZIA)$ Paxalisib被授予快速通道指定，用于治疗携带PI3K通路突变的实体瘤脑转移瘤，并与放疗相结合查看全文
Kazia Therapeutics(KZIA)今天 04:35
$Kazia Therapeutics(KZIA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-102940 Act: 34 Size: 407 KB 网页链接查看全文
Kazia Therapeutics(KZIA)今天 04:35
$Kazia Therapeutics(KZIA)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001193125-24-102947 Act: 33 Size: 417 KB 网页链接查看全文
Kazia Therapeutics(KZIA)03-27 20:45
$Kazia Therapeutics(KZIA)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001193125-24-078293 Act: 33 Size: 403 KB 网页链接查看全文
Kazia Therapeutics(KZIA)03-27 20:35
$Kazia Therapeutics(KZIA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-078281 Act: 34 Size: 4 MB 网页链接查看全文
Kazia Therapeutics(KZIA)03-26 20:05
$Kazia Therapeutics(KZIA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-077110 Act: 34 Size: 27 KB 网页链接查看全文
Kazia Therapeutics(KZIA)02-21 22:25
$Kazia Therapeutics(KZIA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-040846 Act: 34 Size: 23 KB 网页链接查看全文
Kazia Therapeutics(KZIA)02-22 05:25
$Kazia Therapeutics(KZIA)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001193125-24-041479 Act: 33 Size: 122 KB 网页链接查看全文
Kazia Therapeutics(KZIA)02-15 04:45
$Kazia Therapeutics(KZIA)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001172661-24-001372 Act: 34 Size: 90 KB 网页链接查看全文
Kazia Therapeutics(KZIA)02-13 07:45
$Kazia Therapeutics(KZIA)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001256071-24-000003 Act: 34 Size: 3 KB 网页链接查看全文
智通财经APP讯，先声药业(02096)发布公告，该公司与Kazia Therapeutics Limited(Kazia)合作的创新药SIM0395(Paxalisib)于2021年12月6日获得中国国家药品监督管理局签发的药物临床试验批准通知书，拟用于胶质母细胞瘤(GBM)，包括新诊断和... 网页链接
$Kazia Therapeutics(KZIA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-102940 Act: 34 Size: 407 KB 网页链接
$Kazia Therapeutics(KZIA)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001193125-24-102947 Act: 33 Size: 417 KB 网页链接
$Kazia Therapeutics(KZIA)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001193125-24-078293 Act: 33 Size: 403 KB 网页链接
$Kazia Therapeutics(KZIA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-078281 Act: 34 Size: 4 MB 网页链接
$Kazia Therapeutics(KZIA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-077110 Act: 34 Size: 27 KB 网页链接
$Kazia Therapeutics(KZIA)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001193125-24-041479 Act: 33 Size: 122 KB 网页链接
$Kazia Therapeutics(KZIA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-040846 Act: 34 Size: 23 KB 网页链接
$Kazia Therapeutics(KZIA)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001172661-24-001372 Act: 34 Size: 90 KB 网页链接
$Kazia Therapeutics(KZIA)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001256071-24-000003 Act: 34 Size: 3 KB 网页链接
$Kazia Therapeutics(KZIA)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-000320 Act: 33 Size: 1 KB 网页链接